RxDoctor Payments Data

Lindsay Wood

Nurse Practitioner · Clermont, FLNPI 1609484609

Payments from drug & device makers

$6,830in general payments, 2019–2025

Across 344 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$989
  • AstraZeneca$823
  • AbbVie$795
  • Lilly USA, LLC$498
  • Bayer$473
  • GSK$425
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$6,830100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,830 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$1,620
Medicare patients
15
Services billed
35

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol68$56,669
OzempicSemaglutide41$45,272
MounjaroTirzepatide30$43,827
EliquisApixaban29$35,473
TrulicityDulaglutide27$30,869
GemtesaVibegron26$19,586
WegovySemaglutide11$16,524
Atorvastatin Calcium182$1,641
Valsartan46$1,361
Levothyroxine Sodium130$1,129
Rosuvastatin Calcium108$1,093
Duloxetine Hcl51$1,064
Celecoxib53$988
Omeprazole86$980
Methenamine Hippurate15$936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$498$74,69657 claims
Novo NordiskOzempic, Wegovy$989$61,79752 claims
AstraZenecaFarxiga$823$56,66968 claims
PfizerEliquis$236$35,47329 claims
Sumitomo Pharma America, Inc.Gemtesa$255$19,58626 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$84$1,129130 claims
AbbVieSynthroid$795$84311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Clermont

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →